MedTrace Logo

N-Acetyl Cysteine in Trichotillomania

NCT00354770 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-02-23

Study results available
· View outcomes & findings →

Summary

This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania

Conditions

  • Trichotillomania

Interventions

DRUG

Placebo

daily

DRUG

N-Acetyl Cysteine

600mg capsules in varying doses for 12 weeks.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jon E Grant, MD, JD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00354770 on ClinicalTrials.gov